Compound 1634
Identifiers
- Canonical SMILES:
COc1ccc(cc1S(=O)(=O)N1CCCC1)-c1c(C)noc1C
- IUPAC name:
4-[4-methoxy-3-(pyrrolidine-1-sulfonyl)phenyl]-3,5-dimethyl-1,2-oxazole
- InChi:
InChI=1S/C16H20N2O4S/c1-11-16(12(2)22-17-11)13-6-7-14(21-3)15(10-13)23(19,20)18-8-4-5-9-18/h6-7,10H,4-5,8-9H2,1-3H3
- InChiKey:
JIXMFEDNAVCSIJ-UHFFFAOYSA-N
External links
![]() 168317807 |
External search
|
|
|
|
|
Bibliography (1)
Pharmacological data
| Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
|---|---|---|---|
| 6 | 1 | 0 | 0 |
Targets
| PPI family | Best activity | Diseases | MMoA |
|---|---|---|---|
| Bromodomain / Histone | 6.00 | cancer | Inhibition |
Physicochemical filters
| Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
|---|---|---|---|---|
| Compliance | ||||
| MW | 336.11 g/mol | |||
| HBA | 6 | |||
| HBD | 0 | |||
| HBA + HBD | 6 | |||
| AlogP | 1.62 | |||
| TPSA | 72.64 | |||
| RB | 3 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
| Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
|---|---|---|---|---|
| 1 | 6 | 1 | 0 | 0 |
Pharmacological data
| Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
|---|---|---|---|---|---|---|---|---|
| 22136469 | 25a | BRD2 P25440 |
|
Biochemical assay | Time-Resolved FRET | pIC50 (half maximal inhibitory concentration, -log10) | 5.80 | |
| 22136469 | 25a | BRD3 Q15059 |
|
Biochemical assay | Time-Resolved FRET | pIC50 (half maximal inhibitory concentration, -log10) | 6.00 | |
| 22136469 | 25a | BRD4 O60885 |
|
Biochemical assay | Time-Resolved FRET | pIC50 (half maximal inhibitory concentration, -log10) | 5.80 | |
| 22136469 | 25a | BRD2 P25440 |
|
Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 5.20 | |
| 22136469 | 25a | BRD3 Q15059 |
|
Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 5.80 | |
| 22136469 | 25a | BRD4 O60885 |
|
Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 5.50 | |
| 22136469 | 25a | BRD4 O60885 |
|
Cellular assay | LPS-stimulated IL6 production | PBMC | pIC50 (half maximal inhibitory concentration, -log10) | 5.60 |
| Ta | Structure | Name | Drugbank ID |
|---|---|---|---|
| 0.6584 | Parecoxib | DB08439 | |
| 0.5641 | Valdecoxib | DB00580 | |
| 0.4159 | 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE | DB06964 | |
| 0.4132 | Glisoxepide | DB01289 | |
| 0.4088 | N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE | DB07527 | |
| 0.3990 | Acetyl sulfisoxazole | DB14033 | |
| 0.3880 | Sulfisoxazole | DB00263 | |
| 0.3820 | (1S)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid | DB07713 | |
| 0.3820 | (1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid | DB07772 | |
| 0.3801 | (3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol | DB06943 | |
| 0.3782 | N-({6-[(4-CYANO-2-FLUOROBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID | DB08112 | |
| 0.3771 | AUY922 | DB11881 | |
| 0.3750 | 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide | DB06961 | |
| 0.3723 | R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid | DB04416 | |
| 0.3636 | N-(biphenyl-4-ylsulfonyl)-D-leucine | DB07446 |




